Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.
Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended
Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option
Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly
Aspen’s Stephen Saad and Sean Capazorio will take part in Investec’s CEO conference in London
Aspen has contributed towards the funding of a new mobile cancer screening clinic for rural
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid
Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.
Aspen’s Stephen Saad and Sean Capazorio will take part in Investec’s CEO conference in London from 14 to 15 November 2024.
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.
Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid unaudited interim Group financial results for the six
Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported a strong performance for the year ended 30 June
Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported creditable unaudited interim Group financial results for the six
Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has closed a multi-currency, syndicated term loan and revolving credit
Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to report reviewed provisional Group financial results for the
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600
Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com